Gitnux/Report 2026

Blood Bank Industry Statistics

The global blood bank market reached $19.12 billion in 2025, explore the figures behind growth, companies, and trends through 2030.
245Statistics
55Sources
12Sections
1Visuals
45mRead
Samuel NorbergWritten by Samuel Norberg·Fact-checked by Maya Johansson
Published
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 31 days

01 Industry overview

The blood bank industry at a glance

The global blood bank market reached $19.12 billion in 2025 and is forecast to grow to $26.59 billion by 2030, while blood availability remains constrained by uneven donation rates and recurring shortages.

$19.12B[46]
Global market size, 2025
6.8%[46]
Forecast CAGR, 2025–2030
120.4M[12]
Global donations, 2023
66.3%[47]
Top five U.S. center share, 2023
Market size
The global blood bank market was valued at $19.12 billion in 2025, according to The Business Research Company. The World Health Organization reported 120.4 million blood donations collected globally in 2023, the latest worldwide collection total available in its 2025 status report.[46][12]
Forecast & CAGR
The market is projected to reach $26.59 billion by 2030, implying a 6.8% compound annual growth rate from 2025 to 2030. The forecast is attributed to rising demand from accidents, transfusions and technology adoption in blood collection and processing.[46]
Market share & regions
North America was the largest regional blood bank market in 2025, while Asia-Pacific was identified as the fastest-growing region. In the global blood supply, high-income countries collected 36% of donations in 2023 despite representing 15% of the world’s population; the Western Pacific region accounted for 31.1 million donations, the largest WHO regional total.[46][12]
Segmentation
The market is segmented by bank type into private and public blood banks; by function into collection, processing, testing, storage and transportation; by product into whole blood, red blood cells, platelets, plasma and white blood cells; and by end user into hospitals, ambulatory surgical centers, clinics and pharmaceutical companies.[46]
Key players & concentration
The U.S. market shows significant collection concentration: the five largest community blood centers collected 66.3% of whole blood and red-blood-cell units in 2023. The American Red Cross said it contributes about 40% of all blood collected in the United States and supplies roughly 2,500 hospitals and transfusion centers.[47][48]
Pricing
In the United States, the mean hospital price for pathogen-reduced apheresis platelets was $701 per unit in 2023, the highest reported price among the blood components covered by the national survey. Smaller hospitals generally paid more per component unit than larger hospitals.[47]
Trends, drivers & challenges
Technology, accident-related demand and expanding component processing are supporting market growth, while supply remains vulnerable to donor shortages, weather disruptions and short product shelf lives. In July 2026, the American Red Cross reported a four-year summer low in donations and said type O-positive inventory had fallen below a one-day supply.[46][48]
Consumer behavior & competition
Only about 3% of the U.S. population eligible to donate gives blood each year, and approximately 6.54 million successful donors were recorded in 2023. Hospitals transfused red blood cells to about 3.65 million U.S. patients in 2023, while competition among suppliers centers on reliable collection, testing, logistics and hospital contracts.[33]
M&A
Consolidation continued among nonprofit blood centers: Vitalant and San Diego Blood Bank announced a strategic merger agreement on January 7, 2026. The organizations said the combination would expand community coverage, integrated support and operational capabilities.[13][49]
Regulation
In the United States, FDA’s Center for Biologics Evaluation and Research regulates blood collection, blood components, related devices and infectious-disease screening, and inspects blood facilities at least every two years. Blood establishments must register and list products within five days of beginning operation and update listings annually and semiannually.[38]
Latest news
The World Health Organization published its Global Status Report on Blood Safety and Availability 2025 in June 2026, based on data from 168 countries and reporting 120.4 million global donations. In October 2026, FDA issued final guidance on donor suitability, donor eligibility and quarantine holds for source plasma; FDA also warned in November 2026 about reported septic transfusion reactions involving platelets since May 2025.[12][38]

02 Ranking

Top 10 Companies in the Blood Bank Industry

The leading companies in the blood bank industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 11, 2026 · Next review December 11, 2026

Verdict

Werfen stands out for donor-recipient compatibility because its serology reagents and automated systems support compatibility work, while Terumo Corporation focuses on blood bags, collection systems, automated processing and pathogen-reduction systems since it supplies pathogen-reduction systems for blood safety.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in transfusion compatibility

    Werfen

    ES

    Ranked #1 · 9.5 · Transfusion compatibility

    Why we picked it: It supplies serology reagents and automated systems used for donor-recipient compatibility in transfusion workflows.

    See in ranking ↓Visit werfen.com ↗

  2. Leader in pathogen reduction

    Terumo Corporation

    JP

    Ranked #2 · 9.1 · Pathogen reduction

    Why we picked it: It supplies the hardware layer for blood collection and processing, including pathogen-reduction systems.

    See in ranking ↓Visit terumo.com ↗

  3. Leader in plasma collection & medicines

    Grifols

    ES

    Ranked #3 · 9.0 · Plasma collection & medicines

    Why we picked it: Its plasma footprint supports plasma-derived medicines and transfusion diagnostics, built around plasma center operations.

    See in ranking ↓Visit grifols.com ↗

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the blood bank industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Werfen

Transfusion compatibility · ES

9.5
2

Terumo Corporation

Pathogen reduction · JP

9.1
3

Grifols

Plasma collection & medicines · ES

9.0
4

QuidelOrtho

Immunohematology diagnostics · US

8.9
5

Octapharma

Plasma collection & medicines · CH

8.9
6

Haemonetics

Blood collection, plasma and hospital blood management · US

8.5
7

JMS

Blood bags, apheresis and cell-therapy products · JP

8.2
8

HLL Lifecare

Blood bags and blood-bank equipment, India · IN

8.2
9

Cerus

Pathogen reduction for transfused blood components · US

8.1
10

Bio-Rad Laboratories

Blood typing and transfusion diagnostics · US

8.0

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 11, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 11). Top 10 companies in the blood bank industry. In Blood Bank Industry Statistics. Gitnux. https://gitnux.org/blood-bank-industry-statistics/#top-companies

report visual · Comparison

Revenue of the largest blood bank companies

Grifols leads with $8.1B in annual revenue (group level, converted to USD).

Grifols$8.1B
Terumo Corporation$7.6B
Octapharma$3.9B
QuidelOrtho$2.7B
Bio-Rad Laboratories$2.6B
Werfen$2.3B
source-verifiedgrifols.com · terumo.com · octapharma.com · s201.q4cdn.com · sec.gov · werfen.com2026

04 Statistics

Technology & Innovation

Technology adoption includes AI performance reported as area-under-the-curve ranges of 0.45–0.97 for predicting transfusion needs over 24–72 hours and automation cutting discard rates (0.1% vs 1.2%).

AI in the blood bank industry

  • 0.45–0.97 was the area-under-the-curve range for five AI studies predicting individual patients’ transfusion needs over 24–72 hours.[1]
  • 0.70–0.91 was the area-under-the-curve range for six AI studies predicting procedure-specific transfusion requirements.[1]
  • 4.18% was the lowest mean absolute percentage error reported across eight AI studies forecasting facility-level blood demand.[1]
  • 0.85 was the highest reported R² value for AI-based regional blood-demand forecasting across five studies.[1]
  • 24 studies published from 2015 to 2025 evaluated AI or machine learning for transfusion-demand prediction in blood banking worldwide.[1]

Automation in the blood bank industry

  • 0.1% was the automated discard rate from whole-blood bag ruptures, compared with 1.2% for semi-automated processing.[2]
  • 9 manual operator interventions were required to separate four whole-blood units with one automated system, versus as many as 26 with semi-automated systems.[3]
  • 0.03% was the automated discard rate for red-cell concentrates below 200 millilitres, compared with 0.5% for semi-automated processing.[2]
  • 76 minutes was the automated processing runtime, compared with 92 minutes for semi-automated whole-blood processing.[2]
  • 17 comparative studies were included in a systematic review of fully automated versus semi-automated whole-blood processing systems worldwide.[2]

Digital Transformation in the healthcare services sector (sector benchmark)

  • Across U.S. non-federal acute care hospitals, 71% used predictive AI integrated into electronic health records in 2024.[4]
  • About 70% of surveyed healthcare executives said investing in technology platforms for digital tools and services would be important or very important in 2025.[5]
  • Among healthcare respondents to KPMG’s global technology survey, 49% were adopting DevSecOps approaches to adapt digital-transformation strategies.[6]
  • About 90% of surveyed global healthcare C-suite executives expected digital technology use to accelerate in 2025, including 50% anticipating a significant impact.[5]
  • Across surveyed healthcare practitioners, 60% believed their organizations’ digital experiences met or exceeded customer needs in 2025.[7]

Technology Adoption in the healthcare services sector (sector benchmark)

  • Across U.S. non-federal acute care hospitals, 92% enabled patients to securely message providers in 2024.[4]
  • Across U.S. non-federal acute care hospitals, 99% enabled patients to view health information electronically in 2024.[4]
  • Across U.S. non-federal acute care hospitals, 70% enabled patient access through applications using HL7 FHIR specifications in 2024.[4]
  • Across U.S. non-federal acute care hospitals, 81% enabled patient access through applications using application-programming-interface specifications in 2024.[4]
  • Across U.S. non-federal acute care hospitals, 84% enabled patients to transmit health information to a third party electronically in 2024.[4]
  • Across U.S. non-federal acute care hospitals, 96% enabled patients to download health information electronically in 2024.[4]

Cloud Computing in the healthcare services sector (sector benchmark)

  • Across surveyed healthcare organizations globally, 31% had a formal cloud strategy and governance framework that was not yet integrated into IT strategy at the end of 2025.[8]
  • Across surveyed healthcare organizations globally, 18% had started adopting cloud services but lacked a comprehensive cloud strategy at the end of 2025.[8]
  • Across surveyed healthcare organizations globally, 15% reported that cloud adoption was fully integrated into business strategy at the end of 2025.[8]
  • Across surveyed healthcare organizations globally, 8% reported minimal cloud adoption without formal strategy or governance at the end of 2025.[8]
  • Across surveyed healthcare organizations globally, 27% reported that cloud operations were well managed and integrated into overall IT strategy at the end of 2025.[8]

Big Data in the healthcare services sector (sector benchmark)

  • Across Brazilian healthcare facilities conducting Big Data analytics, 48% used social-media data in 2024.[9]
  • Across Brazilian healthcare facilities conducting Big Data analytics, 77% used in-house staff rather than external providers in 2024.[9]
  • Across Brazilian healthcare facilities conducting Big Data analytics, 65% used patient demographics, forms, or medical-record data in 2024.[9]
  • Across Brazilian healthcare facilities conducting Big Data analytics, 72% used data from smart devices or sensors in 2024.[9]

05 Statistics

Data & Analytics

Data governance and data quality show measurable friction, with 50% of U.S. abstractors reporting inaccuracies hamper clinical registry efforts in 2024 and 72% reporting governance using approved policy and standards in 2025.

Business intelligence in the blood bank industry

  • 5 of 9 blood-management dashboards reviewed in a BEST Collaborative study were interactive, allowing users to engage directly with performance information.[2]
  • 7 of 9 blood-management dashboards reviewed in the BEST Collaborative study provided filtering or zoom functionality for hierarchical health-system metrics.[2]
  • 7 activity groups organize the International Society of Blood Transfusion’s 50 quality indicators for blood establishments and hospital blood banks.[2]
  • 50 quality indicators were defined in the 2023 International Society of Blood Transfusion framework for blood establishments and hospital blood banks.[2]

Data Quality in the healthcare services sector (sector benchmark)

  • 50% of U.S. healthcare clinical data abstractors reported that data inaccuracies hamper clinical registry efforts in 2024.[10]
  • 75% of U.S. healthcare organizations represented in the survey predominantly used clinical registry data for quality and process improvement in 2024.[10]
  • 8% of U.S. healthcare organizations rated their provider data as excellent in 2022.[11]
  • 40% of U.S. healthcare clinical data abstractors reported that incomplete data hampers clinical registry efforts in 2024.[10]
  • 40% of U.S. healthcare clinical data abstractors reported that manual data entry hampers clinical registry efforts in 2024.[10]

Data Governance in the healthcare services sector (sector benchmark)

  • 72% of healthcare organizations operated governance using approved policy and standards frameworks in 2025.[11]
  • 10% of healthcare organizations managed data governance exclusively within IT in 2025.[11]
  • 38% of healthcare organizations had formal data and information quality-management statements in 2025.[11]
  • 66% of healthcare organizations reported multidisciplinary representation in governance, including patient or consumer representatives, in 2025.[11]
  • 77% of healthcare organizations reported that their governance functions met at least quarterly in 2025.[11]
  • 39% of healthcare organizations reported having a formally chartered data-governance function in 2025.[11]

KPIs in the blood bank industry

  • 0.2% was the lowest platelet-concentrate expiry rate observed at Aragón’s Blood and Tissue Bank after software implementation for processing and stock management.[1]
  • 50 quality indicators are available for KPI selection and monitoring in blood establishments and hospital blood banks under the 2023 ISBT framework.[2]

06 Statistics

Strategy & Growth

Supply and capacity remain strategic: only 49 of 168 reporting countries produced plasma-derived medicinal products using domestically collected plasma in 2023.

Growth in the blood bank industry

  • Voluntary unpaid donors accounted for more than 85% of the estimated 120 million blood donations collected globally in 2023.[12]
  • The median whole-blood donation rate was 4.5 donations per 1,000 people in low-income countries in 2023.[12]
  • The median whole-blood donation rate was 28.9 donations per 1,000 people in high-income countries in 2023.[12]
  • Global blood collections increased by nearly 19% between 2013 and 2023, reaching approximately 120 million donations in 2023.[12]

Differentiation in the blood bank industry

  • Only 49 of 168 reporting countries produced plasma-derived medicinal products using plasma collected domestically in 2023.[12]
  • The median plasma-fractionation volume was 5.4 litres per 1,000 population across 36 reporting countries in 2023.[12]
  • Plasma fractionation volume ranged from 0.3 to 55.4 litres per 1,000 population across 36 reporting countries in 2023.[12]

Mergers and acquisitions in the blood bank industry

  • Vitalant and San Diego Blood Bank announced an agreement to merge on January 8, 2026.[13]
  • Grifols acquired 100% of Haema Plasma Kft. for €35 million on October 31, 2024.[14]
  • Grifols acquired approximately 26 plasma collection centers and 10 blood-donation centers in the United States through its 2019 acquisition of the Interstate Blood Bank Group.[14]
  • Grifols acquired the remaining 51% of the Interstate Blood Bank Group in 2019 for €89 million.[14]

Strategic partnerships in the blood bank industry

  • Grifols acquired a 49.19% interest in Interstate Blood Bank, Inc., a 48.97% interest in Bio-Blood Components, Inc. and a 48.90% interest in Plasma Biological Services in 2016 for $100 million.[14]
  • Grifols’ 2018 plasma-supply agreement covered plasma from approximately 60 Biotest and Haema collection centers.[14]
  • Vitalant and San Diego Blood Bank announced a strategic merger partnership intended to combine national reach with regional blood-service expertise in January 2026.[13]
  • Grifols paid an additional $10 million for an option to acquire the remaining 51% of the Interstate Blood Bank Group in 2016.[14]

07 Statistics

People & Workforce

Workforce constraints remain a measurable variable, with a 12.6% overall vacancy rate in U.S. blood bank and transfusion-medicine departments in 2024 and an anticipated 14.2% five-year retirement rate.

Hiring in the blood bank industry

  • 12.6% was the overall vacancy rate in U.S. blood bank and transfusion-medicine departments in the 2024 laboratory vacancy survey.[15]
  • 73% of U.S. blood bank and transfusion-medicine departments required certification for laboratory positions in 2024.[15]
  • 9.5% was the supervisor vacancy rate in U.S. blood bank and transfusion-medicine departments in 2024.[15]
  • 13.1% was the staff vacancy rate in U.S. blood bank and transfusion-medicine departments in 2024.[15]

Employee retention in the blood bank industry

  • 2.4 percentage points was the reported reduction across NHS Blood and Transplant’s blood-donation workforce following retention work in 2023–2024.[16]
  • 14.2% was the anticipated five-year retirement rate among U.S. blood bank and transfusion-medicine personnel surveyed in 2024.[15]
  • 20.9% was the anticipated five-year retirement rate for supervisors in U.S. blood bank and transfusion-medicine departments surveyed in 2024.[15]
  • 12.8% was NHS Blood and Transplant’s employee-turnover rate in April 2024.[17]

Remote Work in the healthcare services sector (sector benchmark)

  • Across U.S. medical groups, 52% reported that 1%–25% of their workforce worked remotely at least 50% of the time.[18]
  • Across U.S. health care and social assistance, 18% of full-time employees worked fully from home during December 2024–March 2025.[19]
  • Across U.S. medical groups, 18% of leaders expected their organization’s share of remote or hybrid jobs to decrease during 2024.[18]
  • Across U.S. medical groups, 22% of leaders expected their organization’s share of remote or hybrid jobs to increase during 2024.[18]

Hybrid Work in the healthcare services sector (sector benchmark)

  • Across U.S. healthcare practitioners and technical roles, 16% had part-time remote availability, equivalent to hybrid availability, in the 2022 McKinsey American Opportunity Survey.[18]
  • Across U.S. health care and social assistance, 24% of full-time employees were in hybrid arrangements during December 2024–March 2025.[19]
  • Across U.S. healthcare support roles, 14% had part-time remote availability, equivalent to hybrid availability, in the 2022 McKinsey American Opportunity Survey.[18]
  • About 6% of U.S. healthcare jobs were hybrid in a 2024 Robert Half survey cited by the Medical Group Management Association.[18]
  • About 12% of nonclinical healthcare administrative and customer-support jobs were hybrid in a 2024 Robert Half survey cited by the Medical Group Management Association.[18]

Upskilling in the blood bank industry

  • 90% was NHS Blood and Transplant’s personal-development-and-performance-review completion rate in April 2024.[17]
  • 95% was NHS Blood and Transplant’s mandatory-training compliance rate in April 2024.[17]
  • 42.3% of surveyed Tanzanian hospital blood-bank staff had received formal blood-banking training during the previous two years.[1]
  • 38.5% of surveyed Tanzanian hospital blood-bank staff had received only on-the-job blood-banking training.[1]
  • 19.2% of surveyed Tanzanian hospital blood-bank staff reported no specific blood-banking training.[1]

Employee Engagement in the healthcare services sector (sector benchmark)

  • Among U.S. healthcare advanced practice providers, 52% felt heard in 2024.[20]
  • Across NHS staff, the national staff-engagement theme score was 6.64 in the second quarter of 2024/25.[21]
  • Across 2.3 million U.S. healthcare workers, employee engagement declined by 0.02 points in 2024.[20]
  • U.S. registered nurses with low teamwork scores were 1.53 times more likely to leave their healthcare organization in 2024.[20]
  • Across U.S. healthcare organizations, employee turnover fell from 20% to 18% in 2024.[20]

DEI in the blood bank industry

  • 30% of Canadian Blood Services’ workforce identified as Asian and/or people of colour in 2023–2024.[22]
  • 14.8% was the share of NHS Blood and Transplant employees from minority ethnic groups in band 8A and above in April 2024.[17]
  • 20% of Canadian Blood Services executives, directors and associate directors were racialized employees in 2023–2024.[22]

08 Statistics

Customer & Sales

Donor participation improvement is tied to engagement actions, including 81.3% return of lapsed donors during an Australian loyalty-program trial versus 26.5% in controls.

Customer experience in the blood bank industry

  • More than 75% of blood donors at one U.S. blood center rated the overall donation process 9 or 10 out of 10.[23]
  • 50% of active Australian Lifeblood donors gave fewer than three times annually before the loyalty-program trial.[24]
  • 4.2 donations per year was the average donation frequency among active Australian Lifeblood donors before the loyalty-program trial.[24]
  • 9.19 out of 10 was the mean overall donation-process satisfaction score among donors at one U.S. blood center.[23]

Customer retention in the blood bank industry

  • 58% was the 12-month return rate for new Australian Lifeblood donors before the loyalty-program trial.[24]
  • 81.3% of lapsed Australian Lifeblood donors returned during the loyalty-program trial, compared with 26.5% in the control group.[24]
  • 75% of Australian Lifeblood donors returned within 12 months before the loyalty-program trial.[24]
  • 66.2% of first-time Australian Lifeblood donors returned to donate during the loyalty-program trial, compared with 24.5% in the control group.[24]

Customer acquisition in the blood bank industry

  • 92,000 new donors were recruited by the Netherlands’ blood service in 2022, exceeding its target of 70,000.[1]
  • 18.9% was the increase in first-time donations per facility per day after Facebook’s blood-donation tool was introduced across participating U.S. facilities.[23]
  • 24% of donations in the promotion arm of a U.S. online-search advertising experiment came from first-time donors, versus 12% in the altruistic arm.[23]
  • 4.0% was the increase in total donations per facility per day after Facebook’s blood-donation tool was introduced across 363 U.S. collection facilities.[23]

Customer loyalty in the blood bank industry

  • 81.3% of lapsed Australian Lifeblood donors reactivated during the Lifeblood Gifts loyalty-program trial, versus 26.5% of controls.[24]
  • 17% was the potential increase in donations estimated from a Dutch blood-bank Facebook engagement intervention among the existing donor base.[1]
  • 66.2% of first-time Australian Lifeblood donors returned during the Lifeblood Gifts loyalty-program trial, versus 24.5% of controls.[24]
  • 37,461 additional donations were associated with the Australian Lifeblood Gifts loyalty-program trial.[24]

Lead generation in the blood bank industry

  • 389,662 Facebook accounts were reached by a two-week blood-donor recruitment campaign in an African market.[25]
  • 1,765 people visited the landing pages during the two-week African blood-donor recruitment campaign.[25]
  • 3.57% was the website-to-registration conversion rate in the two-week African blood-donor recruitment campaign.[25]
  • 63 people completed the registration form to become blood donors after visiting the African campaign landing pages.[25]
  • 0.45% was the advertisement-to-website click rate in the two-week African blood-donor recruitment campaign.[25]

09 Statistics

Marketing & Brand

Demand generation is tracked through paid-media and reach, with 54 million paid-media impressions delivered by a U.S. blood-donation campaign through March 2023.

Marketing in the blood bank industry

  • 11,800 organic engagements were generated by the U.S. Giving = Living blood-donation campaign through March 2023.[26]
  • 54 million paid-media impressions were delivered by the U.S. Giving = Living blood-donation campaign through March 2023.[26]
  • 66.7 million people were reached organically by the U.S. Giving = Living blood-donation campaign through March 2023.[26]
  • 676,000 paid-media clicks were generated by the U.S. Giving = Living blood-donation campaign through March 2023.[26]

Digital marketing in the blood bank industry

  • 4.5 million YouTube views were generated by the U.S. Giving = Living blood-donation campaign through March 2023.[26]
  • 328.7 million donated-media impressions were generated by the U.S. Giving = Living blood-donation campaign through March 2023.[26]
  • $4.3 million was the reported value of donated media for the U.S. Giving = Living blood-donation campaign through March 2023.[26]

Social media in the blood bank industry

  • 4.5 million YouTube views were recorded by the U.S. Giving = Living blood-donation campaign through March 2023.[26]
  • 11,800 organic social-media engagements were recorded by the U.S. Giving = Living blood-donation campaign through March 2023.[26]
  • 66.7 million people were reached by organic social-media content in the U.S. Giving = Living blood-donation campaign through March 2023.[26]

Influencer Marketing in the healthcare services sector (sector benchmark)

  • 50% of healthcare and pharmaceutical marketers reported dedicated, growing creator/influencer budgets in 2026, compared with 58% globally.[27]
  • 8.57 million influencer posts about the health industry generated a 1.07% average engagement rate globally in 2023.[28]
  • 33% of U.S.-focused health and wellness influencers promoted a product, service or subscription in more than half of their posts in 2026.[29]
  • 38% of posts from U.S.-focused health and wellness influencers promoted a product, service or subscription in 2026.[29]
  • 50% of U.S. physicians surveyed had changed prescribing choices based on healthcare influencer or KOL content on social media in 2024.[30]

10 Statistics

Operations & Execution

Operational outcomes include expiry and discard metrics, including a lowest platelet expiry rate of 0.2% after software for processing and stock management in Aragón.

Process optimization in the blood bank industry

  • 0.2% was the lowest platelet-expiry rate observed after software for blood processing and platelet-stock management was implemented in Aragón, Spain.[1]
  • 13.3% was the increase in annual platelet-concentrate production at Spain’s Blood and Tissue Bank of Aragón between 2013 and 2023.[1]
  • 9 mL was the average additional plasma volume recovered per donation in Aragón in 2023 compared with 2015 after technology implementation.[1]
  • 16.0% was the decrease in annual red-cell-concentrate production at Spain’s Blood and Tissue Bank of Aragón between 2013 and 2023.[1]

Operational efficiency in the blood bank industry

  • 15.6% of collected blood units were discarded in the WHO African Region’s 2022 survey.[31]
  • 59.7% of whole blood collected in the WHO African Region in 2022 was separated into blood components.[31]
  • 100% of platelet concentrates were treated with pathogen-reduction technology at Aragón’s blood bank from 2020 onward.[1]

Quality management in the blood bank industry

  • 99.9% of blood units collected and transfused in the WHO African Region in 2022 were screened for HIV and hepatitis B.[31]
  • 97.1% of blood units collected and transfused in the WHO African Region in 2022 were screened for syphilis.[31]
  • 97.3% of blood units collected and transfused in the WHO African Region in 2022 were screened for hepatitis C.[31]
  • 7.6% of blood donations were deferred for various reasons in the WHO African Region’s 2022 survey.[31]

Supply chain in the blood bank industry

  • 4.5 donations per 1,000 people was the median blood-donation rate in low-income countries in 2023.[12]
  • 36% of global blood donations in 2023 were collected in high-income countries, which represented 15% of the world’s population.[12]
  • 120.4 million blood donations were collected worldwide in 2023.[12]
  • 28.9 donations per 1,000 people was the median blood-donation rate in high-income countries in 2023.[12]

Outsourcing / Offshoring in the healthcare services sector (sector benchmark)

  • 20% of U.S. medical-group leaders planned to outsource or automate some revenue-cycle-management activities in 2024, according to an MGMA poll with 262 responses.[18]
  • 29% of global healthcare providers used third-party providers for remote patient monitoring in 2024, based on a survey of 28 healthcare-provider executives.[32]
  • 18% of U.S. medical-group leaders planned to outsource or automate patient communications in contact centers in 2024, according to an MGMA poll with 262 responses.[18]
  • 54% of global healthcare providers used third-party providers for supply-chain services in 2024, based on a survey of 28 healthcare-provider executives.[32]
  • 43% of global healthcare providers used third-party providers for payroll services in 2024, based on a survey of 28 healthcare-provider executives.[32]

11 Statistics

Finance & Pricing

Cost pressures and margins vary over time, including an aggregate operating margin for U.S. blood centers of -0.3% in 2018 and 2.1% in 2013.

Pricing strategy in the blood bank industry

  • $135 million was the estimated total cost of Zika testing for U.S. blood and platelet donations beginning in August 2016.[33]
  • $1.3 billion was the approximate reduction in U.S. blood-center revenues associated with the reported decline in blood use by 2015.[26]
  • 25% was the approximate reduction in U.S. blood use reported by the federal blood advisory committee by 2015, contributing to higher unit costs.[26]

Cost reduction in the blood bank industry

  • 2.1% was the aggregate operating margin of U.S. blood centers in 2013, according to America’s Blood Centers’ financial-ratio survey.[33]
  • 12% was the projected reduction in blood-production costs from an integrated demand-forecasting and optimization plan compared with its benchmark plan.[24]
  • -0.3% was the aggregate operating margin of U.S. blood centers in 2018, according to America’s Blood Centers’ financial-ratio survey.[33]
  • 15% was the projected reduction in red-blood-cell production under the optimized blood-supply plan compared with the benchmark plan.[24]

Profitability in the blood bank industry

  • -1.0% was the aggregate operating margin of U.S. blood centers in 2015, according to America’s Blood Centers’ financial-ratio survey.[33]
  • 0.7% was the aggregate operating margin of U.S. blood centers in 2016, according to America’s Blood Centers’ financial-ratio survey.[33]
  • 1.2% was the aggregate operating margin of U.S. blood centers in 2014, according to America’s Blood Centers’ financial-ratio survey.[33]
  • -1.3% was the aggregate operating margin of U.S. blood centers in 2017, according to America’s Blood Centers’ financial-ratio survey.[33]

Financial planning in the blood bank industry

  • 54% was the reported peak blood-product wastage after the surge in donations and cancellation of elective surgeries in 2020.[26]
  • 30% was the reported rapid revenue decline that U.S. blood centers faced during the COVID-19 shock in 2020.[26]

12 Statistics

Product & Service

Product throughput and processing outcomes are quantified, including 132,000 blood units collected by the American Red Cross Central and Southern Ohio region in 2023.

Product development in the blood bank industry

  • EUR 426 million was invested in research and development by Grifols in 2025 across its plasma-derived medicines, diagnostic solutions and other products, globally.[34]
  • 98% of blood collected in high-income countries was separated into components in 2023, compared with 52% in low-income countries, according to WHO.[12]
  • 13.3% was the increase in annual platelet-concentrate production at Aragón’s Blood and Tissue Bank between 2013 and 2023 after technology deployment, Spain.[1]
  • EUR 7.1 million was Finnish Blood Service turnover from plasma material in 2024, up 4.7% from 2023, reflecting product-development activity in plasma-derived materials.[35]

Product lifecycle in the blood bank industry

  • 65% of the 2024 cost of one Finnish blood bag was attributable to donation activities, with laboratory activities contributing 17% and production 11%.[35]
  • 55% of Grifols waste was recovered in 2025 across the company’s operations, a lifecycle indicator covering materials after use.[34]
  • 36% of the lifecycle emissions from red-blood-cell transfusion in England came from transportation, the largest single stage, at 2.8 kg CO2e per unit.[23]
  • 7.56 kg CO2e was the estimated lifecycle carbon footprint of one red-blood-cell unit transfused in England, covering donation, transport, testing, storage, transfusion and disposal, in 2022.[23]

After-sales in the blood bank industry

  • EUR 4.8 million was Finnish Blood Service turnover from cell and tissue therapy services in 2024, up 6.4% from 2023.[35]
  • 19.8% was the increase in Haemonetics hospital revenue in fiscal 2024, including transfusion-management services and related disposables, worldwide.[14]
  • 132,000 blood units were collected by the American Red Cross Central and Southern Ohio region at nearly 5,500 community blood drives and six fixed sites in 2023.[36]
  • 560,000 blood products were handled by the American Red Cross Columbus laboratory in 2026, supporting hospital and patient service delivery in central Ohio.[36]

Value proposition in the blood bank industry

  • 132 million people were treated with Grifols products and diagnostic solutions in 2025, according to the company’s global impact reporting.[34]
  • 120.4 million blood donations were collected globally in 2023, providing the core supply proposition of blood establishments and transfusion services.[12]
  • 6.8 times was Grifols’ reported improvement in quality of life per treatment-related investment in 2025, calculated using its social-return methodology.[34]
  • USD 28.72 billion was the estimated value generated for patients by Grifols in 2025, according to its social-return analysis.[34]

13 Statistics

Sustainability & Ethics

Sustainability metrics are reported alongside operations, including 56% of Grifols electricity consumption from renewable sources in 2025 and a 6% reduction in emissions intensity across scopes 1, 2, and 3.

Sustainability in the blood bank industry

  • More than 1 in 7 countries reported having neither dedicated government budget allocations nor cost-recovery mechanisms for blood services in the latest WHO assessment.[12]
  • 35% of water was treated before discharge by Grifols’ biopharma business in 2025.[34]
  • 56% of Grifols electricity consumption came from renewable sources in 2025, while the company reported no coal or nuclear electricity use.[34]
  • 6% was Grifols’ reduction in emissions intensity across scopes 1, 2 and 3 in 2025, compared with its reporting baseline.[34]

ESG in the blood bank industry

  • 34% of Grifols board members were women in 2025, while 50% of directors were independent.[34]
  • 98% of Grifols employees held permanent contracts in 2025, according to the company’s ESG reporting.[34]
  • 95% of Grifols supplier spending was represented by suppliers evaluated on ESG criteria in 2025.[34]
  • 98% of Grifols’ workforce received training in 2025, including more than 7 million training hours.[34]

Ethics in the blood bank industry

  • 80 countries collected more than 90% of their blood supply from voluntary unpaid donors in 2023, according to WHO data.[12]
  • 59 countries remained more than 50% dependent on family-replacement or paid blood donors in 2023, according to WHO.[12]
  • 63% of blood-screening laboratories participated in external quality-assessment schemes for transfusion-transmissible-infection testing in 2023.[12]
  • 68% of hospitals performing transfusions had systems for reporting adverse transfusion events in 2023, according to WHO.[12]

CSR in the blood bank industry

  • EUR 8.5 million was provided by Grifols in 2025 to support patient associations.[34]
  • More than 1,000 community and social-action initiatives were conducted by Grifols in 2025, including activities linked to donation centers and their communities.[34]
  • EUR 21.2 million worth of products were donated by Grifols in 2025 to support patients and communities.[34]
  • 6,200 hours of volunteering were reported by Grifols in 2025 across its community and social-action activities.[34]

Circular economy in the blood bank industry

  • 27% of plasma recovered from whole-blood donations was fractionated for plasma-derived medicinal products in the 36 reporting countries in 2023.[12]
  • 35% of water was treated before discharge by Grifols’ biopharma business in 2025, supporting resource-reuse and pollution-prevention objectives.[34]
  • 55% of Grifols waste was recovered in 2025, according to the company’s environmental reporting.[34]
  • 9 millilitres of additional plasma per donation were recovered on average at Aragón’s Blood and Tissue Bank in 2023 compared with 2015 after software-supported processing improvements.[1]

Carbon footprint in the blood bank industry

  • 10.3 million kg CO2e was the estimated annual carbon footprint of red-blood-cell transfusions in England, based on 1.36 million units transfused annually.[23]
  • 5.67 kg CO2 per useful donation was the estimated 2020 carbon footprint of that Spanish blood-service operation.[37]
  • 2.8 kg CO2e per red-blood-cell unit came from transportation in England, representing 36% of the transfusion lifecycle footprint.[23]
  • 130,315.84 kg CO2 was the estimated 2020 carbon footprint of a Spanish blood-service operation covering 22,952 donations.[37]

15 Statistics

Globalization & Expansion

Regional supply capacity varies, with only 49 of 168 reporting countries producing plasma-derived medicinal products from domestically collected plasma in 2023.

Globalization in the blood bank industry

  • 23 Latin American and Caribbean countries collected 9,212,861 blood units in 2023, 15.5% more than in 2020.[45]
  • 120.4 million blood donations were collected worldwide in 2023, with 36% collected in high-income countries that represented 15% of the global population.[12]
  • 119 countries reported that all plasma-derived medicinal products were imported or that no such products were used in 2023.[12]
  • Only 49 of 168 reporting countries produced plasma-derived medicinal products from plasma collected within the reporting country in 2023.[12]

Supplier management in the blood bank industry

  • Grifols acquired 100% of Haema Plasma Kft. for €35.0 million on October 31, 2024, after previously controlling the subsidiary.[14]
  • Grifols acquired a plasma-donation center in Saskatoon, Canada, for approximately €8.0 million in 2023.[14]
  • Grifols acquired four plasma donor centers from Kedplasma in Germany on May 31, 2019.[14]
  • Grifols’ 2018 plasma-supply agreement covered plasma collected from approximately 60 collection centers owned by Biotest Pharmaceuticals and Haema in the United States and Germany.[14]

Stakeholder management in the blood bank industry

  • 80 countries collected more than 90% of their blood supply from voluntary unpaid donors in 2023.[12]
  • Systems for reporting adverse transfusion events were present in 68% of hospitals performing transfusions in 2023.[12]
  • Blood transfusion committees were present in 40% of hospitals performing transfusions worldwide in 2023, providing a formal stakeholder structure for clinical blood use.[12]
  • 59 countries collected more than 50% of their blood supply from family/replacement or paid donors in 2023.[12]

Distribution channels in the blood bank industry

  • 21.5 million litres of plasma from 36 reporting countries were fractionated for plasma-derived medicinal products in 2023.[12]
  • Apheresis accounted for 16.8% of donations in high-income countries in 2023, compared with 2.7% in upper-middle-income countries.[12]
  • 92% of 116 million reported global donations in 2023 were whole-blood donations, while 7.8% were collected through apheresis.[12]
  • Apheresis represented 12.2% of donations in the WHO European Region and 10.9% in the Western Pacific Region in 2023.[12]

Key questions about the blood bank industry

How large is the global blood bank market in 2025, and what is the 2030 forecast?
The global blood bank market reached $19.12 billion in 2025 and is forecast to grow to $26.59 billion by 2030.
What growth rate does the industry forecast for 2025–2030?
The forecast implies a 6.8% compound annual growth rate from 2025 to 2030.
Which companies lead the blood bank industry?
Werfen stands out for donor-recipient compatibility because its serology reagents and automated systems support compatibility work, while Terumo Corporation focuses on blood bags, collection systems, automated processing and pathogen-reduction systems since it supplies pathogen-reduction systems for blood safety.
What does recent technology performance show for transfusion-demand prediction and forecasting?
AI studies reported area-under-the-curve ranges of 0.45–0.97 for predicting transfusion needs over 24–72 hours, and 4.18% lowest mean absolute percentage error across eight studies forecasting facility-level blood demand.
How concentrated is U.S. community blood center collection, and what share of donations do leading organizations represent?
In 2023, the five largest community blood centers collected 66.3% of whole blood and red-blood-cell units. The American Red Cross contributes about 40% of all blood collected in the United States and supplies roughly 2,500 hospitals and transfusion centers.
What operational risk has been reported for U.S. donations and type O-positive inventory by July 2026?
In July 2026, the American Red Cross reported a four-year summer low in donations and said type O-positive inventory had fallen below a one-day supply.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 11). Blood Bank Industry Statistics. Gitnux. https://gitnux.org/blood-bank-industry-statistics
MLA
Samuel Norberg. "Blood Bank Industry Statistics." Gitnux, 11 Nov 2026, https://gitnux.org/blood-bank-industry-statistics.
Chicago
Samuel Norberg. 2026. "Blood Bank Industry Statistics." Gitnux. https://gitnux.org/blood-bank-industry-statistics.

Sources & references

55 sources cited across this report

  1. pmc.ncbi.nlm.nih.gov
  2. onlinelibrary.wiley.com
  3. perpus-utama.poltekkes-malang.ac.id
  4. healthit.gov
  5. deloitte.com
  6. kpmg.com
  7. business.adobe.com
  8. go.rackspace.com
  9. cetic.br
  10. carta.healthcare
  11. intersystems.com
  12. who.int
  13. vitalant.org
  14. sec.gov
  15. academic.oup.com
  16. assets.publishing.service.gov.uk
  17. nhsbtdbe.blob.core.windows.net
  18. mgma.com
  19. wfhresearch.com
  20. pressganey.com
  21. england.nhs.uk
  22. blood.ca
  23. pubmed.ncbi.nlm.nih.gov
  24. doi.org
  25. pure.uva.nl
  26. hhs.gov
  27. brand-news.it
  28. media.sproutsocial.com
  29. pewresearch.org
  30. sermo.com
  31. iris.who.int
  32. tcs.com
  33. americasblood.org
  34. grifols.com
  35. vuosikertomus.veripalvelu.fi
  36. redcross.org
  37. nataonline.com
  38. fda.gov
  39. ache.org
  40. proofpoint.com
  41. ponemonsullivanreport.com
  42. kff.org
  43. hfmmagazine.com
  44. sophos.com
  45. paho.org
  46. thebusinessresearchcompany.com
  47. stacks.cdc.gov
  48. redcrossblood.org
  49. sandiegobloodbank.org
  50. werfen.com
  51. terumo.com
  52. octapharma.com
  53. haemonetics.gcs-web.com
  54. jms.cc
  55. lifecarehll.com